Claims
- 1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, pharmaceutically effective amounts of a compound having adenosine A1/A2 agonistic activity, and a sodium-hydrogen exchanger inhibitory compound.
- 2. The pharmaceutical composition according to claim 1 wherein the compound having adenosine A1/A2 agonistic activity is a compound of the formula
- 3. The pharmaceutical composition according to claim 1 wherein the sodium-hydrogen exchanger inhibitory compound is selected from the group consisting of cariporide, eniporide, zoniporide, BMS-284640, BIIB-513, BIIB-722CI, EMD-85131, KB-R9032, MS-31-038, SL-59.1227, SM20550, SMP-300, T-559 and TY-12533.
- 4. The pharmaceutical composition according to claim 1 wherein the sodium-hydrogen exchanger inhibitory compound is cariporide.
- 5. The pharmaceutical composition according to claim 1 wherein the compound having adenosine A1/A2 agonistic activity is AMP579 and the sodium-hydrogen exchanger inhibitory compound is cariporide.
- 6. A method of providing cardioprotection in a patient in need thereof comprising administering to said patient the pharmaceutical composition according to claim 1.
- 7. A method of protecting against reperfusion injury in a patient in need thereof comprising administering to said patient the pharmaceutical composition according to claim 1.
- 8. A method of protecting against ischemic injury in a patient in need thereof comprising administering to said patient the pharmaceutical composition according to claim 1.
- 9. A method of providing cardioprotection prior to, during, or following cardiac surgery in a patient in need thereof comprising administering to said patient the pharmaceutical composition according to claim 1.
- 10. A method of providing cardioprotection in a patient in need thereof prior to, during, or following ischemic attack comprising administering to said patient the pharmaceutical composition according to claim 1.
- 11. A kit for providing cardioprotection in a patient in need thereof, said kit comprising a plurality of separate containers, wherein at least one of said containers contains a compound having adenosine A1/A2 agonistic activity and at least another of said containers contains a sodium-hydrogen exchanger inhibitory compound, and said containers optionally contain a pharmaceutical carrier.
- 12. A kit according to claim 11 wherein of said containers at least one of said containers should contain the compound having adenosine A1/A2 agonistic activity without the presence of sodium-hydrogen exchanger inhibitory compound, and at least another of said containers should contain the sodium-hydrogen exchanger inhibitory compound without the presence of the compound having adenosine A1/A2 agonistic activity.
- 13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount, or less than pharmaceutically effective amount of a compound having adenosine A1/A2 agonistic activity and a pharmaceutically effective amount, or less than a pharmaceutically effective amount of a sodium-hydrogen exchanger inhibitory compound, provided that the composition is pharmaceutically effective.
Priority Claims (1)
Number |
Date |
Country |
Kind |
0203596.2 |
Feb 2002 |
GB |
|
Parent Case Info
[0001] This application is a continuation of International Application No. PCT/US02/35096, filed Nov. 1, 2002, which claims the benefit of U.S. Provisional Application No. 60/336,315, filed Nov. 2, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60336315 |
Nov 2001 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/US02/35096 |
Nov 2002 |
US |
Child |
10835964 |
Apr 2004 |
US |